🇺🇸 FDA
Pipeline program

Olpasiran, Placebo for AMG 890

20230191

Phase 3 small_molecule active

Quick answer

Olpasiran, Placebo for AMG 890 for Cardiovascular Disease is a Phase 3 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen Technology (Ireland) UC
Indication
Cardiovascular Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials